Andrea Stojakovic,Sergey Trushin,Anthony Sheu,Layla Khalili,Su-Youne Chang,Xing Li,Trace Christensen,Jeffrey L. Salisbury,Rachel E. Geroux,Benjamin Gateno,Padraig J. Flannery,Mrunal Dehankar,Cory C. Funk,Jordan Wilkins,Anna Stepanova,Tara O’Hagan,Alexander Galkin,Jarred Nesbitt,Xiujuan Zhu,Utkarsh Tripathi,Slobodan Macura,Tamar Tchkonia,Tamar Pirtskhalava,James L. Kirkland,Rachel A. Kudgus,Renee A. Schoon,Joel M. Reid,Yu Yamazaki,Takahisa Kanekiyo,Song Zhang,Emirhan Nemutlu,Petras Dzeja,Adam Jaspersen,Ye In Christopher Kwon,Michael K. Lee,Eugenia Trushina

Abstract:Communications Biology, Published online: 26 February 2024; doi:10.1038/s42003-024-05810-9 Author Correction: Partial inhibition of mitochondrial complex I ameliorates Alzheimer's disease pathology and cognition in APP/PS1 female mice

Correction to: The Novel Small Molecule TRVA242 Stabilizes Neuromuscular Junction Defects in Multiple Animal Models of Amyotrophic Lateral Sclerosis

Correction: Corrigendum: CMT2D Neuropathy is Linked to the Neomorphic Binding Activity of Glycyl-Trna Synthetase

Author Correction: Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy

Author Correction: Reversing a model of Parkinson’s disease with in situ converted nigral neurons

Correction: Cell Therapy: A Safe and Efficacious Therapeutic Treatment for Alzheimer's Disease in APP+PS1 Mice.

Author Correction: Structural insights into the activation of metabotropic glutamate receptors

Author Correction: Humanizing the Mdx Mouse Model of DMD: the Long and the Short of It

Correction: Corrigendum: Opportunities and challenges in modeling human brain disorders in transgenic primates

Correction To: Efficient and Rapid Conversion of Human Astrocytes and ALS Mouse Model Spinal Cord Astrocytes into Motor Neuron-Like Cells by Defined Small Molecules

Correction: Fan et al. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. Molecules 2022, 27, 7524

Erratum: Favorable efficacy and reduced acute neurotoxicity by antisense oligonucleotides with 2',4' -BNA/LNA with 9-(aminoethoxy)phenoxazine

Corrigendum to “Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice” [Bioactive materials 6 (2021) 529–542]

Author Correction: Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model

Correction: Musumeci et al. Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer's Disease. Biomedicines 2022, 10, 985

Correction: Barik et al., LRP4 Is Critical for Neuromuscular Junction Maintenance

Author Correction: Tau-targeting antisense oligonucleotide MAPT Rx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial

Correction: Isatin-based benzyloxybenzene derivatives as monoamine oxidase inhibitors with neuroprotective effect targeting neurodegenerative disease treatment

Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors

Author Correction: NMNAT2 is a druggable target to drive neuronal NAD production

Author Correction to ‘pharmacologically Targeting Molecular Motor Promotes Mitochondrial Fission for Anti-Cancer’ [acta Pharm Sin B 11 (2021) 1853–1866]

Author Correction: Partial inhibition of mitochondrial complex I ameliorates Alzheimer's disease pathology and cognition in APP/PS1 female mice